Transfusion of blood components containing ABO-incompatible plasma does not lead to higher mortality in civilian trauma patients.
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
29
04
2020
revised:
10
06
2020
accepted:
09
07
2020
pubmed:
10
9
2020
medline:
29
6
2021
entrez:
9
9
2020
Statut:
ppublish
Résumé
This study investigated the effect on mortality of transfusing ABO-incompatible plasma from all sources during trauma resuscitation. Demographic, transfusion, and survival data were retrospectively extracted on civilian trauma patients. Patients were divided by receipt of any quantity of ABO-incompatible plasma from any blood product (incompatible group) or receipt of solely ABO-compatible plasma (compatible group). The primary outcome was 30-day mortality, while other outcomes included 6- and 24-hour mortality. Mixed-effects logistic regression was used to model the effect of various predictor variables, including receipt of incompatible plasma, on mortality outcomes. Nine hospitals contributed data on a total of 2618 trauma patients. There were 1282 patients in the incompatible group and 1336 patients in the compatible group. In both the unadjusted and adjusted models, the 6-hour, 24-hour, and 30-day mortality rates were not significantly different between these groups. The patients in the incompatible group were then divided into high volume (>342 mL) and low volume (≤342 mL) incompatible plasma recipients. In the adjusted model, the high-volume group had higher 24-hour mortality when the Trauma Injury Severity Score survival prediction was >50%. Mortality at 6 hours and 30 days was not higher in this model. The low-volume group did not have increased mortality at any of the time points in this adjusted model. The transfusion of incompatible plasma in civilian trauma resuscitation does not lead to higher 30-day mortality. The finding of higher mortality in a select group of recipients in the secondary analysis warrants further study.
Sections du résumé
BACKGROUND
This study investigated the effect on mortality of transfusing ABO-incompatible plasma from all sources during trauma resuscitation.
METHODS
Demographic, transfusion, and survival data were retrospectively extracted on civilian trauma patients. Patients were divided by receipt of any quantity of ABO-incompatible plasma from any blood product (incompatible group) or receipt of solely ABO-compatible plasma (compatible group). The primary outcome was 30-day mortality, while other outcomes included 6- and 24-hour mortality. Mixed-effects logistic regression was used to model the effect of various predictor variables, including receipt of incompatible plasma, on mortality outcomes.
RESULTS
Nine hospitals contributed data on a total of 2618 trauma patients. There were 1282 patients in the incompatible group and 1336 patients in the compatible group. In both the unadjusted and adjusted models, the 6-hour, 24-hour, and 30-day mortality rates were not significantly different between these groups. The patients in the incompatible group were then divided into high volume (>342 mL) and low volume (≤342 mL) incompatible plasma recipients. In the adjusted model, the high-volume group had higher 24-hour mortality when the Trauma Injury Severity Score survival prediction was >50%. Mortality at 6 hours and 30 days was not higher in this model. The low-volume group did not have increased mortality at any of the time points in this adjusted model.
CONCLUSION
The transfusion of incompatible plasma in civilian trauma resuscitation does not lead to higher 30-day mortality. The finding of higher mortality in a select group of recipients in the secondary analysis warrants further study.
Substances chimiques
ABO Blood-Group System
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2517-2528Informations de copyright
© 2020 AABB.
Références
Yazer MH, Spinella PC. Review of low titer group O whole blood use for massively bleeding patients around the world in 2019. ISBT Sci Ser. 2019;14:276-281.
Yazer MH, Spinella PC. The use of low-titer group O whole blood for the resuscitation of civilian trauma patients in 2018. Transfusion. 2018;58:2744-2746.
Dunbar NM, Yazer MH, Biomedical Excellence for Safer Transfusion Collaborative. A possible new paradigm? A survey-based assessment of the use of thawed group A plasma for trauma resuscitation in the United States. Transfusion. 2016;56:125-129.
Dunbar NM, Yazer MH. Safety of the use of group A plasma in trauma: the STAT study. Transfusion. 2017;57:1879-1884.
American Association of Blood Bank (AABB). Standards for blood banks and transfusion services. 32nd ed. Bethesda, MD: AABB, 2019.
Lozano M, Cid J. The clinical implications of platelet transfusions associated with ABO or Rh(D) incompatibility. Transfus Med Rev. 2003;17:57-68.
Cid J, Harm SK, Yazer MH. Platelet transfusion - the art and science of compromise. Transfus Med Hemother. 2013;40:160-171.
Josephson CD, Castillejo MI, Grima K, Hillyer CD. ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies. Transfus Apher Sci. 2010;42:83-88.
Quillen K, Sheldon SL, Daniel-Johnson JA, Lee-Stroka AH, Flegel WA. A practical strategy to reduce the risk of passive hemolysis by screening plateletpheresis donors for high-titer ABO antibodies. Transfusion. 2011;51:92-96.
Reitz KM, Moore HB, Guyette FX, et al. Prehospital plasma in injured patients is associated with survival principally in blunt injury: results from two randomized prehospital plasma trials. J Trauma Acute Care Surg. 2020;88:33-41.
Seheult JN, Anto V, Alarcon LH, Sperry JL, Triulzi DJ, Yazer MH. Clinical outcomes among low-titer group O whole blood recipients compared to recipients of conventional components in civilian trauma resuscitation. Transfusion. 2018;58:1838-1845.
Flora JD Jr. A method for comparing survival of burn patients to a standard survival curve. J Trauma. 1978;18:701-705.
Boyd CR, Tolson MA, Copes WS. Evaluating trauma care: the TRISS method. Trauma Score and the Injury Severity Score. J Trauma. 1987;27:370-378.
Zielinski MD, Johnson PM, Jenkins D, Goussous N, Stubbs JR. Emergency use of prethawed Group A plasma in trauma patients. J Trauma Acute Care Surg. 2013;74:69-74; discussion -5.
Chhibber V, Greene M, Vauthrin M, Bailey J, Weinstein R. Is group A thawed plasma suitable as the first option for emergency release transfusion? (CME). Transfusion. 2014;54:1751-1755. quiz 0.
Zielinski MD, Schrager JJ, Johnson P, et al. Multicenter comparison of emergency release group A versus AB plasma in blunt-injured trauma patients. Clin Transl Sci. 2015;8:43-47.
Shanwell A, Andersson TM, Rostgaard K, et al. Post-transfusion mortality among recipients of ABO-compatible but non-identical plasma. Vox Sang. 2009;96:316-323.
Inaba K, Branco BC, Rhee P, et al. Impact of ABO-identical vs ABO-compatible nonidentical plasma transfusion in trauma patients. Arch Surg. 2010;145:899-906.
Baker SP, O'Neill B, Haddon W Jr, et al. The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma. 1974;14:187-196.